386 related articles for article (PubMed ID: 34407787)
61. Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells.
Ryu CS; Kwak HC; Lee JY; Oh SJ; Phuong NT; Kang KW; Kim SK
Biochem Pharmacol; 2013 Jan; 85(2):197-206. PubMed ID: 23123664
[TBL] [Abstract][Full Text] [Related]
62. Adenylate Kinase 4 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an m
Liu X; Gonzalez G; Dai X; Miao W; Yuan J; Huang M; Bade D; Li L; Sun Y; Wang Y
Mol Ther; 2020 Dec; 28(12):2593-2604. PubMed ID: 32956623
[TBL] [Abstract][Full Text] [Related]
63. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
[TBL] [Abstract][Full Text] [Related]
64. Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition.
Kim JA; Kim MR; Kim O; Phuong NT; Yun J; Oh WK; Bae K; Kang KW
Food Chem Toxicol; 2012 Oct; 50(10):3625-34. PubMed ID: 22842120
[TBL] [Abstract][Full Text] [Related]
65. Elevated CRB3 expression suppresses breast cancer stemness by inhibiting β-catenin signalling to restore tamoxifen sensitivity.
Li P; Feng C; Chen H; Jiang Y; Cao F; Liu J; Liu P
J Cell Mol Med; 2018 Jul; 22(7):3423-3433. PubMed ID: 29602199
[TBL] [Abstract][Full Text] [Related]
66. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
67. Lycorine weakens tamoxifen resistance of breast cancer via abrogating HAGLR-mediated epigenetic suppression on VGLL4 by DNMT1.
Zhai J; Jiang JF; Shi L
Kaohsiung J Med Sci; 2023 Mar; 39(3):278-289. PubMed ID: 36606584
[TBL] [Abstract][Full Text] [Related]
68. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Kannan N; Kang J; Kong X; Tang J; Perry JK; Mohankumar KM; Miller LD; Liu ET; Mertani HC; Zhu T; Grandison PM; Liu DX; Lobie PE
Neoplasia; 2010 Dec; 12(12):1041-53. PubMed ID: 21170268
[TBL] [Abstract][Full Text] [Related]
69. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
Knowlden JM; Hutcheson IR; Barrow D; Gee JM; Nicholson RI
Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379
[TBL] [Abstract][Full Text] [Related]
70. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
71. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
72. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
73. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
Choi HJ; Lui A; Ogony J; Jan R; Sims PJ; Lewis-Wambi J
Breast Cancer Res; 2015 Jan; 17(1):6. PubMed ID: 25588716
[TBL] [Abstract][Full Text] [Related]
74. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
Li XN; Liu AH; Tang X; Ren Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
[TBL] [Abstract][Full Text] [Related]
75. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
[TBL] [Abstract][Full Text] [Related]
76. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
Maraqa L; Cummings M; Peter MB; Shaaban AM; Horgan K; Hanby AM; Speirs V
Clin Cancer Res; 2008 Jan; 14(2):405-11. PubMed ID: 18223215
[TBL] [Abstract][Full Text] [Related]
77. Altered radiation responses of breast cancer cells resistant to hormonal therapy.
Luzhna L; Lykkesfeldt AE; Kovalchuk O
Oncotarget; 2015 Jan; 6(3):1678-94. PubMed ID: 25682200
[TBL] [Abstract][Full Text] [Related]
78. Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development.
Madden SF; Cremona M; Farrelly AM; Low WH; McBryan J
Cancer Gene Ther; 2023 Feb; 30(2):324-334. PubMed ID: 36266450
[TBL] [Abstract][Full Text] [Related]
79. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
Ikeda K; Horie-Inoue K; Ueno T; Suzuki T; Sato W; Shigekawa T; Osaki A; Saeki T; Berezikov E; Mano H; Inoue S
Sci Rep; 2015 Aug; 5():13170. PubMed ID: 26255816
[TBL] [Abstract][Full Text] [Related]
80. MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells.
Lee MH; Koh D; Na H; Ka NL; Kim S; Kim HJ; Hong S; Shin YK; Seong JK; Lee MO
Autophagy; 2018; 14(5):812-824. PubMed ID: 29130361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
